Royalty Pharma (RPRX) Operating Margin (2019 - 2026)
Royalty Pharma (RPRX) posted Operating Margin of 89.29% for Q1 2026, up 43.0% sequentially from 62.44% in Q4 2025, and down 472.0% YoY from 24.0% in Q1 2025.
Royalty Pharma (RPRX) Operating Margin (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Operating Margin for 8 years, with the latest figure at 89.29% in Q1 2026.
- Quarterly Operating Margin fell 472.0% year-over-year to 89.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 65.08% (down 1886.0% YoY) and the FY2025 annual result came in at 65.58%, up 848.0% from the prior year.
- Operating Margin improved to 89.29% in Q1 2026 per RPRX's latest filing, from 62.44% in the prior quarter.
- Over five years, Operating Margin peaked at 130.17% in Q3 2024 and troughed at 85.31% in Q4 2022.
- A 5-year average of 52.09% and a median of 60.9% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2023: Operating Margin sank 11196 bps in 2022, then surged 18814 bps in 2023.
- Over 5 years, Operating Margin stood at 85.31% in 2022, then jumped by 221 bps to 102.82% in 2023, then tumbled by 41 bps to 60.9% in 2024, then gained by 3 bps to 62.44% in 2025, then jumped by 43 bps to 89.29% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 89.29%, 62.44%, and 70.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -25,380.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.75% |
| Mar 31, 2026 | 89.29% |
| Dec 31, 2025 | 62.44% |
| Sep 30, 2025 | 70.11% |
| Jun 30, 2025 | 36.26% |
| Mar 31, 2025 | 94.01% |
| Dec 31, 2024 | 60.90% |
| Sep 30, 2024 | 130.17% |
| Jun 30, 2024 | 50.19% |
| Mar 31, 2024 | -12.99% |
| Dec 31, 2023 | 102.82% |
| Sep 30, 2023 | 28.24% |
| Jun 30, 2023 | 46.24% |
| Mar 31, 2023 | 70.03% |
| Dec 31, 2022 | -85.31% |
| Sep 30, 2022 | 33.52% |
| Jun 30, 2022 | 70.49% |
| Mar 31, 2022 | 39.09% |
| Dec 31, 2021 | 26.65% |
| Sep 30, 2021 | 51.74% |